Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study Journal Article


Authors: Bluemke, D. A.; Sahani, D.; Amendola, M.; Balzer, T.; Breuer, J.; Brown, J. J.; Casalino, D. D.; Davis, P. L.; Francis, I. R.; Krinsky, G.; Lee, F. T. Jr; Lu, D.; Paulson, E. K.; Schwartz, L. H.; Siegelman, E. S.
Article Title: Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study
Abstract: To assess prospectively the efficacy and safety of postcontrast magnetic resonance (MR) imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid (Gd-EOB-DTPA) compared with that of precontrast MR imaging in patients who are known to have or are suspected of having liver lesions and who are scheduled for hepatic surgery. MATERIALS AND METHODS: Investigational review board approval and written informed consent were obtained. HIPAA went into effect after data collection. A total of 172 patients were enrolled. After precontrast MR imaging, 169 patients (94 men, 75 women; mean age, 61 years; age range, 19-84 years) received an intravenous bolus of 25 μmol/kg Gd-EOB-DTPA and underwent dynamic gradient-recalled-echo and delayed MR imaging 20 minutes after injection. Arterial and portal phase computed tomography (CT) were performed within 6 weeks of MR imaging. The standard of reference was surgery with intraoperative ultrasonography (US) and biopsy and/or pathologic evaluation of resected liver segments and/or 3-month follow-up of nonresected segments if intraoperative US was not available. Three blinded reviewers and unblinded site investigators identified liver lesions on segment maps. The Wilcoxon signed rank test was used to compare differences in per-patient sensitivity of precontrast and postcontrast MR images. Adverse events were recorded, and patient monitoring and laboratory assay were performed at time of injection and up to 24 hours after contrast material administration. RESULTS: At MR imaging, 316 lesions were identified in 131 patients. In 77% (P = .012), 72% (P = .15), and 71% (P = .027) of patients for readers 1, 2, and 3, respectively, more lesions were seen at precontrast and postcontrast MR imaging combined than at precontrast MR imaging alone. Sensitivity values for blinded readings were significantly greater at postcontrast MR imaging than at precontrast MR imaging for two of three blinded readers. For all blinded readers, combined precontrast and postcontrast MR images showed no difference in sensitivity compared with helical CT scans. The use of MR imaging, however, yielded fewer patients with at least one false-positive lesion (37%, 31%, and 34% of patients for readers 1, 2, and 3, respectively) than did helical CT (45%, 36%, and 43% of patients for readers 1, 2, and 3, respectively). CONCLUSION: Compared with precontrast MR imaging, postcontrast MR imaging with Gd-EOB-DTPA demonstrated improved sensitivity for lesion detection in the majority of blinded readers, with no substantial adverse events. © RSNA, 2005.
Keywords: adult; aged; aged, 80 and over; middle aged; major clinical study; clinical trial; drug efficacy; drug safety; liver cell carcinoma; side effect; liver neoplasms; united states; nuclear magnetic resonance imaging; follow up; magnetic resonance imaging; prospective study; sensitivity and specificity; edema; computer assisted tomography; phase 2 clinical trial; tomography, x-ray computed; patient monitoring; vasodilatation; backache; dizziness; dyspnea; injection site reaction; heart palpitation; liver metastasis; diagnostic value; intraoperative period; laboratory test; taste disorder; contrast medium; contrast media; liver cancer; bile duct carcinoma; safety; headache; gadolinium dtpa; liver hemangioma; liver adenoma; false positive reactions; liver cyst; spiral computer assisted tomography; multicenter studies; sweat gland disease; clinical trials, phase iii; gadoxetic acid; hydatid cyst
Journal Title: Radiology
Volume: 237
Issue: 1
ISSN: 0033-8419
Publisher: Radiological Society of North America, Inc.  
Date Published: 2005-10-01
Start Page: 89
End Page: 98
Language: English
DOI: 10.1148/radiol.2371031842
PUBMED: 16126918
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 88" - "Export Date: 24 October 2012" - "CODEN: RADLA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lawrence H Schwartz
    306 Schwartz